Rani Therapeutics price to sales ratio RANI

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 17.3×
4-year median: 71.2×
Against its 4-year history: 0th; percentile: 0 is its lowest day, 100 its highest
4-year range: 17.3× to 199×
Peer median: 1.4×

Rani Therapeutics' price to sales ratio is 17.3× as of Oct 23, 2026.

That is below its 4-year median of 71.2×, lower than on 100% of days in the last 4 years.

Over that time it ranged from 17.3× in Oct 2026 to 199× in May 2022.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.3×	17.3×	142×
2025	142×	136×	190×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	192×	170×	199×

Against its peers

Companies in Drug Manufacturers - General nearest Rani Therapeutics' size, closest first, today.

Company	Price to sales ratio
RANIRani Therapeutics	17.3×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
ATNMActinium Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Rani Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.